Related Experiment Video

Updated: Oct 9, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes

J A Puma1, M H Sketch

  • 1Division of Cardiology, Duke University Medical Center, Box 3157, Durham, NC 27710, USA. joepuma1@aol.com

The Journal of the American Osteopathic Association
|February 24, 2001
PubMed

Insights

Acute coronary syndromes, a leading cause of death, are treated with aspirin and newer intravenous antiplatelet agents. Fibrinolytic therapy is beneficial for ST-segment-elevation myocardial infarction but risky for other acute coronary syndromes.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Acute coronary syndromes (ACS) are a significant cause of mortality globally.
  • ACS encompasses unstable angina, non-ST-segment-elevation myocardial infarction, and ST-segment-elevation myocardial infarction, representing a spectrum of disease severity.
  • Pathophysiologically, ACS is linked to intracoronary thrombus formation.

Purpose of the Study:

  • To review the current understanding of acute coronary syndromes.
  • To discuss the role of antiplatelet agents and fibrinolytic therapy in managing ACS.
  • To highlight the differential treatment strategies based on ACS subtype.

Main Methods:

  • Literature review of acute coronary syndromes.
  • Analysis of treatment strategies including antiplatelet and fibrinolytic therapies.
  • Evaluation of therapeutic outcomes based on disease severity.

Main Results:

  • Aspirin is foundational for all ACS management.
  • Intravenous antiplatelet agents improve outcomes in unstable angina and non-ST-segment-elevation myocardial infarction.
  • Fibrinolytic therapy reduces mortality in ST-segment-elevation myocardial infarction but carries risks in other ACS types.

Conclusions:

  • Optimal management of acute coronary syndromes requires tailored therapeutic approaches.
  • Antiplatelet therapy is crucial, with newer agents offering specific benefits.
  • Careful consideration of fibrinolytic therapy is necessary, balancing benefits against risks for different ACS presentations.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...